[{"data":1,"prerenderedAt":221},["ShallowReactive",2],{"$f17fxuc4jrgnso":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":23,"top_modalities":55,"top_diseases":77,"top_companies":104,"key_results":128,"trends":208,"previous_editions":217,"comparison":172,"highlighted_classes":218},1,"elcc-2026","ELCC","elcc","European Lung Cancer Congress 2026",2026,"Oncology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},489,246,58,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 4":20,"Phase 2\u002F3":21,"Phase 3":22},14,12,44,2,3,37,[24,28,32,35,38,42,44,47,50,53],{"name":25,"count":26,"share":27},"PDCD1",54,22,{"name":29,"count":30,"share":31},"EGFR",47,19,{"name":33,"count":34,"share":17},"CD274",35,{"name":36,"count":18,"share":37},"VEGFA",5,{"name":39,"count":40,"share":41},"ALK",11,4,{"name":43,"count":40,"share":41},"ERBB2",{"name":45,"count":46,"share":41},"MET",10,{"name":48,"count":49,"share":41},"ROS1",9,{"name":51,"count":52,"share":21},"KRASG12C",8,{"name":54,"count":52,"share":21},"RET",[56,60,64,67,69,71,73,75],{"name":57,"count":58,"share":59},"Small molecules",135,55,{"name":61,"count":62,"share":63},"Monoclonal antibodies",100,41,{"name":65,"count":66,"share":40},"Bispecific antibodies",28,{"name":68,"count":27,"share":49},"Antibody-drug conjugates",{"name":70,"count":21,"share":4},"Vaccines",{"name":72,"count":20,"share":4},"Cell therapies",{"name":74,"count":20,"share":4},"Peptides",{"name":76,"count":20,"share":4},"Radiopharmaceuticals",[78,82,86,88,91,94,96,98,100,102],{"name":79,"count":80,"share":81},"non-small cell lung cancer (NSCLC)",192,78,{"name":83,"count":84,"share":85},"small cell lung cancer (SCLC)",33,13,{"name":87,"count":52,"share":21},"bronchial carcinoma",{"name":89,"count":90,"share":21},"Non-small cell lung cancer adenocarcinoma (NSCLC)",7,{"name":92,"count":93,"share":20},"Pulmonary squamous cell carcinoma",6,{"name":95,"count":41,"share":20},"brain metastases",{"name":97,"count":41,"share":20},"Non-small cell lung cancer (NS-NSCLC)",{"name":99,"count":41,"share":20},"pleural mesothelioma",{"name":101,"count":20,"share":4},"Carcinomatous Meningitis (CM)",{"name":103,"count":20,"share":4},"large cell neuroendocrine carcinoma (LCNEC)",[105,109,111,114,116,118,120,122,124,126],{"name":106,"count":107,"share":108},"AstraZeneca",36,15,{"name":110,"count":27,"share":49},"Bristol Myers Squibb",{"name":112,"count":113,"share":90},"Merck",18,{"name":115,"count":108,"share":93},"Pfizer",{"name":117,"count":40,"share":41},"Genentech",{"name":119,"count":40,"share":41},"Hansoh Pharmaceutical Group",{"name":121,"count":46,"share":41},"Daiichi Sankyo",{"name":123,"count":90,"share":21},"Eli Lilly",{"name":125,"count":93,"share":20},"BioNTech",{"name":127,"count":41,"share":20},"Akeso",[129,136,143,149,156,162,168,175,181,188,196,202],{"title":130,"drug":131,"company":106,"phase":133,"disease":79,"finding":134,"url":135},"Osimertinib (osi) with or without chemotherapy (CTx) as first-line treatment in EGFR-mutant (EGFRm) advanced NSCLC with concurrent TP53 mutations (TOP study)",{"name":132,"slug":132},"osimertinib","Phase 3","Osi + CTx significantly improved PFS versus osi (HR 0.44; 95% CI 0.32, 0.61; p\u003C0.001; 59% maturity).","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21526\u002FPresentation\u002F48",{"title":137,"drug":138,"company":140,"phase":133,"disease":79,"finding":141,"url":142},"First-line limertinib versus gefitinib in EGFR-mutated advanced NSCLC: Updated overall survival results from a randomized, double-blind, phase III trial",{"name":139,"slug":139},"limertinib","Jiangsu Aosaikang Pharmaceutical","The median OS was 43.3 months (95% CI: 35.9–48.2) with limertinib versus 34.5 months (95% CI: 28.7–39.3) with gefitinib (HR 0.78; 95% CI: 0.58–1.05; p=0.1013).","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21526\u002FPresentation\u002F636",{"title":144,"drug":145,"company":125,"phase":133,"disease":92,"finding":147,"url":148},"Anti-tumor activity of gotistobart compared to docetaxel in patients with metastatic squamous non-small cell lung cancer (sqNSCLC) progressing on PD-(L)1 inhibitors: Stage 1 PRESERVE-003 phase III trial",{"name":146,"slug":146},"gotistobart","Median PFS was similar (2.4 m vs 2.6 m), but the 12-m PFS rate was 25% for gotistobart and 0% for docetaxel, with a HR of 0.69 (95% CI, 0.42, 1.13) favoring gotistobart.","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21526\u002FPresentation\u002F836",{"title":150,"drug":151,"company":153,"phase":133,"disease":83,"finding":154,"url":155},"Adebrelimab plus chemotherapy (chemo) as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC): 5-year update of the phase III CAPSTONE-1 study",{"name":152,"slug":152},"adebrelimab","Jiangsu HengRui Medicine Co., Ltd.","The OS benefit with adebrelimab + chemo vs placebo + chemo was maintained (HR 0.73 [95% CI 0.60–0.89], 1-sided nominal p=0.0008).","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21526\u002FPresentation\u002F217",{"title":157,"drug":158,"company":127,"phase":133,"disease":79,"finding":160,"url":161},"Health-related quality of life in patients previously treated with an EGFR-TKI from HARMONi: A phase III trial of ivonescimab vs placebo plus chemotherapy",{"name":159,"slug":159},"ivonescimab","TTD in GHS\u002FQoL was also comparable in both arms, with a longer TTD for IVO + CT than PBO + CT, median 7.0 mos vs 6.5 mos (HR 0.90, 95% CI 0.73-1.12).","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21526\u002FPresentation\u002F620",{"title":163,"drug":164,"company":106,"phase":133,"disease":83,"finding":166,"url":167},"Subsequent treatment (tx) patterns and impact on patient (pt) outcomes in the phase III ADRIATIC study of consolidation durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage SCLC (LS-SCLC)",{"name":165,"slug":165},"durvalumab","TFST was prolonged with D vs P (HR 0.72 [95% CI 0.58–0.90]; median [95% CI] 26.6 [19.2–37.3] vs 15.3 [12.0–19.9] mo), as was PFS2 (HR 0.66 [95% CI 0.49–0.88]; median [95% CI] not reached (NR) [NR–NR] vs 37.6 [25.3–NR] mo).","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21526\u002FPresentation\u002F209",{"title":169,"drug":170,"company":172,"phase":133,"disease":83,"finding":173,"url":174},"IMforte: Subsequent treatment (Tx) following first-line maintenance (1Lm) with lurbinectedin (lurbi) + atezolizumab (atezo) or atezo in extensive stage small cell lung cancer (ES-SCLC)",{"name":171,"slug":171},"lurbinectedin",null,"The OS benefit favouring lurbi + atezo over atezo was maintained after adjusting for survival bias introduced by 2L lurbi (HR, 0.68 [95% CI: 0.52, 0.90]).","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21526\u002FPresentation\u002F222",{"title":176,"drug":177,"company":112,"phase":133,"disease":79,"finding":179,"url":180},"Exploratory analysis of participants without pathological complete response (pCR) in the KEYNOTE-671 study of perioperative pembrolizumab (pembro) in early-stage NSCLC after 5 years of follow-up",{"name":178,"slug":178},"pembrolizumab","The HR for EFS was 0.69 (95% CI, 0.57–0.83), favoring the pembro vs placebo arm.","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21526\u002FPresentation\u002F404",{"title":182,"drug":183,"company":185,"phase":133,"disease":79,"finding":186,"url":187},"Impact of genomic alterations on clinical outcomes with first-line cemiplimab + chemotherapy for advanced NSCLC: An analysis from EMPOWER-Lung 3",{"name":184,"slug":184},"cemiplimab","Regeneron Pharmaceuticals","In STK11 wt pts, cemi+chemo showed OS benefit vs chemo (median OS 18.1 vs 7.6 months [mo]; HR=0.49, 95% CI: 0.31–0.78).","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21526\u002FPresentation\u002F676",{"title":189,"drug":190,"company":172,"phase":193,"disease":79,"finding":194,"url":195},"UV1 vaccine with standard of care PD-1 checkpoint inhibitor as first-line treatment for non-small cell lung cancer (NSCLC): A randomized phase II trial",{"name":191,"slug":192},"UV1","uv1","Phase 2","TTR and ORR were 2 mo and 53.3 % (UV1+SoC) vs 3 mo and 46.7 % (SoC) (HR=0.96, 95% CI: 0.35-2,67), and median DoR was 17 mo (UV1+SoC) vs 11 mo (SoC) (HR=0.79; 95% CI: 0.25-2.46).","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21526\u002FPresentation\u002F715",{"title":197,"drug":198,"company":172,"phase":193,"disease":83,"finding":200,"url":201},"Serplulimab consolidation after concurrent hypofractionated chemoradiotherapy for limited-stage small cell lung cancer",{"name":199,"slug":199},"serplulimab","The median PFS was 27.5 months (95% CI: 15.7-NR) since initiation of serplulimab, with 1- and 2-year PFS rates of 63.6% (95% CI: 52.1-77.7%) and 54.0% (95% CI: 42.2-69.1%), respectively.","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21526\u002FPresentation\u002F210",{"title":203,"drug":204,"company":125,"phase":193,"disease":83,"finding":206,"url":207},"Phase II study of first-line pumitamig (PD-L1 × VEGF-A bsAb) plus chemotherapy for extensive-stage small cell lung cancer (ES-SCLC): Updated efficacy and safety results",{"name":205,"slug":205},"pumitamig","Four pts (8%) discontinued treatment due to pumitamig-related TEAEs.","https:\u002F\u002Fcattendee.abstractsonline.com\u002Fmeeting\u002F21526\u002FPresentation\u002F225",{"summary":209,"bullets":211},[210],"Small molecules were the most frequent modality (55% of drug-linked abstracts). PDCD1 was the most frequent target (22%). Non-small cell lung cancer (NSCLC) was the most frequent disease (78%).",[212,213,214,215,216],"AstraZeneca had the largest company share (15% of drug-linked abstracts).","Antibody-drug conjugates accounted for 9% of drug-linked abstracts.","Bispecific antibodies accounted for 11% of drug-linked abstracts.","Monoclonal antibodies were the next most frequent modality (41%).","EGFR was the next most frequent target (19%).",[],[219,220],{"name":68,"count":27,"share":49,"previous_count":172,"previous_share":172,"direction":172},{"name":65,"count":66,"share":40,"previous_count":172,"previous_share":172,"direction":172},1793970603102]